Clinical Trials
21 trialsNCT04093323 2026-02-25
Polarized Dendritic Cell (aDC1) Based Treatment, Interferon Alpha-2, Rintatolimod, and Celecoxib for the Treatment of HLA-A2+ Refractory Melanoma
Roswell Park Cancer Institute
Phase 2 Terminated
NCT04162873 2025-02-12
Celecoxib Through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer
University of Utah
Phase 2 Terminated
NCT03643744 2024-12-19
Photodynamic Therapy-Induced Immune Modulation: Part III
Wright State University
Phase 1 Terminated
NCT00151476 2024-09-04
Observational Familial Adenomatous Polyposis Registry Study In Patients Receiving Celecoxib Compared to Control Patients
Pfizer
Terminated
NCT01545141 2023-10-27
Chemokine-Modulatory Regimen for Recurrent Resectable Colorectal Cancer
Roswell Park Cancer Institute
Phase 1/2 Terminated
NCT00665457 2023-09-13
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
University of Nebraska
Phase 2 Terminated
NCT02054104 2022-01-26
Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum
National Institutes of Health Clinical Center (CC)
Phase 1/2 Terminated
NCT00585312 2021-02-21
CHIP
Pfizer
Phase 3 Terminated
NCT00088972 2018-08-10
S0300, Celecoxib in Preventing Breast Cancer in Premenopausal Women
SWOG Cancer Research Network
Phase 2 Terminated
NCT01041781 2018-07-23
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT01705106 2018-05-30
Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies
University of Chicago
Phase 1 Terminated
NCT01284504 2018-03-16
Effect of Celecoxib on Perioperative Inflammatory Response in Colon Cancer
Stanford University
Phase NA Terminated
NCT01729923 2018-01-16
ADAPT
University of Washington
Phase 2 Terminated
NCT00520845 2017-03-20
Celecoxib and Docetaxel or Pemetrexed in Treating Patients With Advanced Recurrent Non-Small Cell Lung Cancer
Vanderbilt-Ingram Cancer Center
Phase 2 Terminated
NCT01555073 2016-07-28
Preemptive Analgesia Following Uterine Artery Embolization
Northwestern University
Phase 4 Terminated
NCT00198081 2016-02-29
Use of Celecoxib in Patients With Intraductal Papillary Mucinous Neoplasms (IPMNs)
Indiana University
Phase 2 Terminated
NCT00305643 2015-12-24
Celecoxib in Preventing Hand/Foot Syndrome Caused By Capecitabine With Metastatic Breast or Colorectal Cancer
M.D. Anderson Cancer Center
Phase 3 Terminated
NCT00250835 2015-09-01
Combination of Oxaliplatin, Capecitabine, and Celecoxib With Concurrent Radiation for Rectal Cancer
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT00068770 2015-03-18
Celecoxib in Patients With Newly Diagnosed GBM Who Are Receiving Anticonvulsant Drugs and Undergoing RT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00527982 2012-12-06
Celecoxib as Adjuvant Biologic Therapy in Patients With Head and Neck and Lung Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00592319 2012-08-31
Celebrex (Celecoxib) Treatment of Laryngeal Papilloma
Boston University
Phase 2 Terminated